TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (NCT04485013)
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab, Cetuximab or FOLFIRI Plus Cetuximab in Patients With Advanced Solid Refractory/Resistant Malignancies
🩺 Plain-English Summary (8th-Grade Level)
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Who can join: Review the eligibility criteria below.
Location: Arizona Oncology Associates — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (41 Sites)
Showing the first 25 of 41 sites.
- Arizona Oncology Associates — Tucson, Arizona
- University of Southern California — Los Angeles, California
- Hoag Memorial Hospital — Newport Beach, California
- Rocky Mountain Cancer Centers — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Christiana Care Helen F. Graham Cancer Center — Newark, Delaware
- John Hopkins Kimmer Cancer Center — Washington D.C., District of Columbia
- Florida Cancer Specialists — Daytona Beach, Florida
- Florida Cancer Specialists — Fleming Island, Florida
- Ocala Oncology Center — Ocala, Florida
- AdventHealth Research Institute — Orlando, Florida
- Illinois Cancer Specialists — Arlington Heights, Illinois
- University of Illinois — Chicago, Illinois
- Indiana University — Indianapolis, Indiana
- Norton Cancer Institute — Louisville, Kentucky
- American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders — Bethesda, Maryland
- Maryland Oncology Hematology — Silver Spring, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- START Midwest — Grand Rapids, Michigan
- Regions Hospital Cancer Care Center — Saint Paul, Minnesota
- Washington University in St Louis — St Louis, Missouri
- Nebraska Cancer Center Oncology Hematology West P.C. — Omaha, Nebraska
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Icahn School of Medicine at Mount Sinai — New York, New York
- Stony Brook University — Stony Brook, New York
📞 Contact the Study Coordinator
Phone: (888) 585-2990
Email: clinicaltrials@tizonatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cancer
- Ovarian Tissue Cryopreservation in Children — Rochester, Minnesota
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study — Aurora, Colorado
- Ex Onc SLED: A Study Utilizing A Weighted Sled for Horizontal Resistance Training — Pittsburgh, Pennsylvania
- An Internet-based Program to Help Cancer Survivors Manage Pain — Fort Smith, Arkansas
- Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors — Toronto, Ontario
- Researching the Effect of Aerobic Exercise on Cancer — Los Angeles, California
Explore by condition: All Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.